Current stock page

Financial Data

VERA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Sep 11, 2026

VERA

Financial Data
Vera Therapeutics, Inc.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 11, 2026
Last price
$35.05
+$1.45 (+4.32%)
Latest market quote
Momentum50
Value
Quality27
Risk Resilience57
Sentiment53
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 11, 2026.

Income statement
8 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0-$256K$1.13M$0-$563K$0$0$0
Operating Income-$112.49M-$125.13M-$94.21M-$83.93M-$80.14M-$57.19M-$48.91M-$49.8M
Net Income-$109.47M-$121.03M-$91.1M-$80.29M-$76.53M-$51.69M-$43.43M-$46.63M
EPS-$1.52-$1.69-$1.39-$1.26-$1.2-$0.81-$0.85-$0.85
Cash flow statement
7 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$100.25M-$106.5M-$69.99M-$61.91M-$54.8M-$54.41M-$39.18M
Capital Expenditure$0-$173K-$102K-$133K-$208K-$187K-$645K
Free Cash Flow-$100.25M-$106.67M-$70.1M-$62.04M-$55.01M-$54.59M-$39.83M
Net Cash Provided By Operating Activities-$100.25M-$106.5M-$69.99M-$61.91M-$54.8M-$54.41M-$39.18M
Balance sheet
7 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$532.98M$621.74M$734.73M$517.5M$578.53M$610.17M$655.68M
Total Debt$75.23M$75.03M$77.31M$77.22M$77.55M$54.47M$54.64M
Cash And Cash Equivalents
Total Liabilities$125.23M$122.04M$130.21M$118.62M$110.25M$75.17M$78.53M
Total Stockholders Equity$407.76M$499.7M$604.52M$398.88M$468.28M$535M$577.16M
Key financial metrics
7 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio-7.06-5.95-9.11-5.77-4.91-7.41-12.44
P/B ratio7.565.755.384.653.212.864.02
P/S ratio0000000
Debt To Equity0.180.150.130.190.170.10.09
Free Cash Flow Yield-3.25%-3.71%-2.15%-3.34%-3.66%-3.57%-1.72%
Financial ratios
7 periods
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio-7.06-5.95-9.11-5.77-4.91-7.41-12.44
P/B ratio7.565.755.384.653.212.864.02
P/S ratio0000000
Return On Equity-26.85%-24.22%-15.07%-20.13%-16.34%-9.66%-7.52%
Debt To Equity0.180.150.130.190.170.10.09

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
-5.84
multipleSep 11, 2026
Pb
6.03
multipleSep 11, 2026
Revenue Growth Yoy
0
percentSep 11, 2026
EPS Growth Yoy
10.06
percentSep 11, 2026
Gross Margin
0
percentSep 11, 2026
Operating Margin
0
percentSep 11, 2026
ROE
-84.13
percentSep 11, 2026
ROIC
-85.78
percentSep 11, 2026
Debt To Equity
0.18
ratioSep 11, 2026
FCF Yield
-13.8
percentSep 11, 2026
Technical indicators
Close
35.05
priceSep 11, 2026
Volume
3,486,004
volumeSep 11, 2026
Rsi14
59.79
indexSep 11, 2026
MACD
0.23
indexSep 11, 2026
MACD Signal
0.09
indexSep 11, 2026
MACD Histogram
0.15
indexSep 11, 2026
Adx14
18.33
indexSep 11, 2026
Sma50
35.22
priceSep 11, 2026
Sma200
39.56
priceSep 11, 2026
Atr14
1.72
priceSep 11, 2026
Historical Volatility
0.59
percentSep 11, 2026
Volume Ma20
2,123,051
volumeSep 11, 2026
Risk measures
Resilience Score
57
score_0_100Sep 11, 2026
Beta
0.95
ratioSep 11, 2026
Volatility Annual
59.41
percentSep 11, 2026
Max Drawdown
-48.1
percentSep 11, 2026
Sharpe Ratio
0.84
ratioSep 11, 2026
Var95
-4.53
percentSep 11, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

VERA Financial Data FAQ

What is Vera Therapeutics, Inc.'s revenue?

Vera Therapeutics, Inc.'s revenue is one of the core financial data points for VERA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Vera Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Vera Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is VERA's EPS?

VERA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Vera Therapeutics, Inc.'s net income?

Vera Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Vera Therapeutics, Inc. generate?

Free cash flow shows how much cash Vera Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Vera Therapeutics, Inc. have?

Cash and debt help frame VERA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.